A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-1

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-1

Discontinued
Phase of Trial: Phase III

Latest Information Update: 25 May 2017

At a glance

  • Drugs Brodalumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms AMVISION-1
  • Sponsors Amgen
  • Most Recent Events

    • 09 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Oct 2015, according to ClinicalTrials.gov record.
    • 09 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Oct 2015, according to ClinicalTrials.gov record.
    • 28 Jul 2015 Planned End Date changed from 1 Apr 2018 to 1 Sep 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top